GuidelineMenopause (New York, N.Y.)
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.
Guideline in Menopause (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04228757 (A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life), which is not on this map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life
Who cites it
57 citing papers in PubMed, 370 citations in OpenAlex.
- Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2015Trial
- Trial
- Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial.Drugs in R&D · 2012Trial
- Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.Clinical drug investigation · 2012Trial
- Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension.Journal of women's health (2002) · 2010Trial
- Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010Trial
- A randomized trial of the effect of estrogen and testosterone on economic behavior.Proceedings of the National Academy of Sciences of the United States of America · 2009Trial
- Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women.Journal of endocrinological investigationTrial
- Investigation of the quality of life and influencing factors among perimenopausal women.Archives of gynecology and obstetrics · 2025Article
- Reproductive aging in biological females: mechanisms and immediate consequences.Frontiers in endocrinology · 2025Review
- Considerations in Premature Menopause: A Review.Cureus · 2024Review
- Prevalence of Age-Related Sensorineural Hearing Loss and Related Factors in Elderly Patients Attending Tertiary Hospital in Tanzania.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Advances in diagnosis and treatment of perimenopausal syndrome.Open life sciences · 2023Review
- The geography of the age at menopause in central Portugal since the early twentieth century.Scientific reports · 2022Article
- Estimates of global research productivity in primary ovarian insufficiency from 2000 to 2021: Bibliometric analysis.Frontiers in endocrinology · 2022Article
- HIV-1 Tat promotes age-related cognitive, anxiety-like, and antinociceptive impairments in female mice that are moderated by aging and endocrine status.GeroScience · 2021Article
- The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.Endocrine · 2019Review
- Article
- Sex hormone therapy and progression of cardiovascular disease in menopausal women.Clinical science (London, England : 1979) · 2016Review
- A survey of the availability in Canadian pharmacy chains of over-the-counter natural health products for menopause symptoms.BMC complementary and alternative medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond.
design: An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement.
results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided.
conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.